My research is mainly focused on the effects of cholesterol, saturated fat and statin drugs on health. If you know anyone who is worried about their cholesterol levels and heart disease, or has been told to take statin drugs you could send them a link to this website, and to my statin or cholesterol or heart disease books.
Independent Health Researcher
Saturday, 28 May 2016
Study title and authors:
Effect Of Statin Therapy On Outcomes In Patients With Acute Lung Injury And Acute Respiratory Distress Syndrome.
Seth R. Bauer, PharmD, Simon W. Lam, PharmD, Anita J. Reddy, MD
This study can be accessed at: http://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2010.181.1_MeetingAbstracts.A1701
Acute lung injury/acute respiratory distress syndrome is a life-threatening medical condition where the lungs can't provide enough oxygen for the rest of the body.
This study investigated the effects of statins on patients diagnosed with acute lung injury/acute respiratory distress syndrome who received treatment in an intensive care unit setting. The study included 187 patients who were divided into three groups:
(i) Patients who received statins before and continued after acute lung injury/acute respiratory distress syndrome diagnosis.
(ii) Patients who received statins before but not after acute lung injury/acute respiratory distress syndrome diagnosis.
(iii) Patients who never had statins.
The study found:
(a) Overall, patients who received statins had a 75% increased risk of death compared to patients who never had statins.
(b) Patients who received statins before and continued after acute lung injury/acute respiratory distress syndrome diagnosis had a 114% increased risk of death compared to patients who never had statins.
(c) Patients who received statins before but not after acute lung injury/acute respiratory distress syndrome diagnosis had a 41% increased risk of death compared to patients who never had statins.
Links to other studies:
Link between statin use and interstitial lung disease
63.5% of patients report experiencing side-effects due to statins
Doctor says statin drug hypersensitivity reactions are potentially life-threatening
Thursday, 26 May 2016
Below is the transcript of the review from the Caduceus Journal (Issue 93 Page 26).
Dr Rajendra Sharma (MB BCh BAO LRCP&S (Ire) MFHom
is a leading Integrated Medical Doctor utilizing conventional, Functional and complementary medicine. His special interest is working with chronic disease and its underlying causes particularly CFS/ME, cancer and other difficult conditions that respond poorly to conventional medicine.
He focuses on optimizing health through nutritional and non-drug medicine and as, until recently, the Secretary to the British Society for Ecological Medicine is involved in environmental health screening (metal toxicity, food allergy, pollution etc.)
Dr Sharma is considered by many as their family doctor and as a generalist works with all medical conditions. He is the author of The Family Encyclopedia of Health and has recently published the quintessential ‘all you need to know’ healthy ageing book, “Live Longer Live Younger”. He has particular links with the media and entertainment industry and over many years has not only provided content and support to the BBC, ITV , Channel 4 and others, but also provided and continues to provide care regularly to many globally acclaimed celebrities. Over his experienced career as Medical Director at the Hale Clinic and The Diagnostic Clinic he has forged new care initiatives. These include the impact of genomics and the environment in optimizing patient protocols, treatment and care plans.
Saturday, 21 May 2016
Doctor says statins may be over prescribed five to six fold when using the American College of Cardiology/American Heart Association faulty risk calculator
Thursday, 19 May 2016
Study title and authors:
Low serum cholesterol concentration and short term mortality from injuries in men and women.
Centre for Public Health Research, Karlstad, Sweden.
Tuesday, 17 May 2016
Friday, 13 May 2016
Wednesday, 11 May 2016
Medical error is responsible for over a quarter of a million deaths and is the third most common cause of death in the US
Sunday, 8 May 2016
Study stopped early because statins increased the risk of acute kidney injury in patients with kidney disease
This study investigated the relationship between short-term high-dose perioperative atorvastatin and acute kidney injury following cardiac surgery. The study included 615 patients (199 statin-naïve and 416 statin-using) and 308 of these were randomized to atorvastatin and 307 to placebo. The average patient age was 67 years.
(i) Patients naive to statin treatment were randomly assigned 80 mg of atorvastatin the day before surgery, 40 mg of atorvastatin the morning of surgery, and 40 mg of atorvastatin daily following surgery or matching placebo.
(ii) Patients already taking a statin prior to study enrolment continued taking the preenrollment statin until the day of surgery, were randomly assigned 80 mg of atorvastatin the morning of surgery and 40 mg of atorvastatin the morning after or matching placebo, and resumed taking the previously prescribed statin on postoperative day 2.
The study found:
(a) After an interim review, the data and safety monitoring board recommended stopping the group naive to statin treatment due to a 235% increased risk of acute kidney injury among these participants with chronic kidney disease receiving atorvastatin.
(b) After a further review, the data and safety monitoring board later recommended stopping for futility, as the data revealed statins were increasing the risk of acute kidney injury by 6% overall and by 61% in statin naïve patients.
(c) Those who took statins had a 25% increased risk of the more serious stage 2 or stage 3 acute kidney injury compared to those who did not take statins.
The study also revealed:
(d) Those given the statins had a 20% increased risk of muscle pain compared to those taking placebo.
(e) Those given the statins had a 44% increased risk of stroke compared to those taking placebo.
(f) Those given the statins had a 11% increased risk of atrial fibrillation compared to those taking placebo.
(g) Those given the statins had a 202% increased risk of in hospital death compared to those taking placebo.
Links to other studies:
Statins increase the risk of diabetes in kidney transplant patients
Statin use is associated with a 30-36% increased incidence of acute and chronic kidney disease
Statin use associated with a 59% increased risk of kidney failure
Sunday, 1 May 2016
This study investigated the involvement of statins in impaired cellular energy production. Mitochondria are the cells power plants, and coenzyme Q10 (ubiquinone) and cytochrome oxidase (complex IV) are vital enzymes needed in cellular energy production.
In a study published in the Journal of the American College of Cardiology, coenzyme Q10 (ubiquinone) was shown to lower cardiovascular deaths by 43% and lower the overall death rate by 42%.
Cytochrome oxidase (Complex 4) deficiency is a condition that can affect several parts of the body, including the muscles used for movement (skeletal muscles), the heart, the brain, or the liver. Cytochrome oxidase deficiency can lead to muscle weakness (myopathy), poor muscle tone (hypotonia), severe brain dysfunction (encephalomyopathy). Approximately one quarter of individuals with cytochrome oxidase deficiency have a type of heart disease that enlarges and weakens the heart muscle (hypertrophic cardiomyopathy). Another possible feature of this condition is an enlarged liver, which may lead to liver failure. Most individuals with cytochrome c oxidase deficiency have a buildup of a chemical called lactic acid in the body (lactic acidosis), which can cause nausea and an irregular heart rate, and can be life-threatening. Many people with cytochrome oxidase deficiency have a loss of mental function, movement problems, hypertrophic cardiomyopathy, eating difficulties, and brain abnormalities. Cytochrome oxidase deficiency is frequently fatal in childhood.
(i) Two patients experiencing muscle problems following treatment with simvastatin (40 mg per day) and cyclosporin (patient 1) and simvastatin (40 mg per day) and itraconazole (patient 2).
(ii) Analysis of the two patients skeletal muscle revealed a decreased ubiquinone status (77 and 132; reference range: 140-580 pmol/mg) and decreased complex IV activity (0.006 and 0.007 reference range: 0.014-0.034).
(iii) To assess statin treatment in the absence of possible pharmacological interference from cyclosporin or itraconazole, primary astrocytes (cells from the central nervous system) were cultured with lovastatin.
(iv) Lovastatin treatment resulted in a decrease in ubiquinone (statin treatment 97.9 versus control 202.9 pmol/mg), and a decrease in complex IV activity (statin treatment 0.008 versus control: 0.011).
Duncan concludes: "These data, coupled with the patient findings, indicate a possible association between statin treatment, decreased ubiquinone status, and loss of complex IV activity".